Heart Matters

Episodi

• 
  Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence 14.09.2026 3min

  Guest: M. Melih Dogan, MD What does current evidence tell us about subcutaneous lipoprotein(a)-lowering therapies? Find out as Dr. M. Melih Dogan shares findings from a recent meta-analysis examining their efficacy, safety, and effects on key lipid parameters, along with the limitations that remain as larger clinical trials continue. He's a Postdoctoral Researcher at East Carolina University Heart Institute, and he spoke about this topic at the 2026 European Society of Cardiology Congress in Munich.
• 
  Exploring AI-Powered ATTR-CM Detection 03.09.2026 5min

  Guest: Bruno Batinica, MD Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.
• 
  Advancing ATTR-CM Identification: Early Findings from TRACE-AI 03.09.2026 4min

  Guest: Bruno Batinica, MD Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of combining modalities to improve positive predictive value, and next steps toward prospective deployment in clinical practice.
• 
  Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights 02.09.2026 9min

  Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Akshay Kumar, MD In cardiothoracic surgery, the need for anticoagulation reversal can arise quickly, and the path forward isn’t always clear. In this case-based discussion with Dr. Brian McDonough, Dr. Akshay Kumar shares his perspective on making anticoagulation reversal decisions across a range of urgent and complex surgical scenarios. Dr. Kumar is a Clinical Assistant Professor in the Department of Cardiothoracic Surgery at the NYU Grossman School of Medicine.
• 
  Navigating ASCVD and Pancreatitis Risk in Severe Hypertriglyceridemia 31.08.2026 15min

  Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrew Freeman, MD, FACC, FACP In this episode of Heart Matters, Dr. Charles Turck is joined by Dr. Andrew Freeman to take a case-based look at severe hypertriglyceridemia and explore how the 2026 American College of Cardiology/American Heart Association Multisociety guideline on dyslipidemia management can help inform clinical decision-making. Together, Dr. Turck and Dr. Freeman follow a hypothetical patient over the course of their treatment journey, discussing how clinicians can effectively identify patients with sHTG at risk of atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis, and how management priorities may evolve over time. Dr. Freeman is a board-certified cardiologist and Director of Cardiovascular Prevention and Wellness, and Clinical Cardiology and Operations at National Jewish Health in Denver, Colorado.
• 
  A More Complete View of Cardiovascular Risk in Women 31.08.2026 5min

  Guest: Noel Bairey Merz, MD Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify elevated risk earlier. Dr. Bairey Merz is the Director of the Barbra Streisand Women’s Health Center, the Linda Joy Pollin Women’s Heart Health Program, and the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Smidt Heart Institute in Beverly Hills, California. She also spoke about this topic at the 2026 European Society of Cardiology Congress.
• 
  Updated AACE Guidance on Managing Dyslipidemia in T2D 27.08.2026 2min

  Guest: Scott D. Isaacs, MD FACP, FACE Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the 2026 AACE diabetes algorithm. Join Dr. Scott Isaacs as he reviews new recommendations on LDL-C goals and individualized care in this population. Dr. Isaacs is the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.
• 
  Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk 27.08.2026 3min

  Guest: Scott D. Isaacs, MD FACP, FACE For patients with diabetes, effective care requires more than just lowering A1C. Dr. Scott Isaacs joins us to discuss the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. He’s the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.
• 
  Applying Guideline Recommendations to ACS Management 26.08.2026 13min

  Host: Steve Jackson, PharmD Guest: Sunil Rao, MD The 2025 American College of Cardiology/American Heart Association Guideline for the Management of Patients With Acute Coronary Syndromes (ACS) reflects more than a decade of new evidence, but what will actually change at the bedside? Tune in to find out as Dr. Sunil Rao, Chair of the Joint Committee on Clinical Practice Guidelines, discusses the recommendations poised to have the greatest clinical impact and practical considerations for implementing them across the continuum of ACS care. Dr. Rao is a Professor of Medicine at the NYU Grossman School of Medicine and the Director of Interventional Cardiology at NYU Langone Health.
• 
  Overcoming Challenges in ATTR-CM Diagnosis 20.08.2026 3min

  Guest: Sumeet Mitter MD, MSc, FACC Even with advances in noninvasive imaging, diagnosing ATTR-CM isn’t always straightforward. That's why Dr. Sumeet Mitter joins us to discuss how we can address key challenges in diagnosis and navigate the path to treatment. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.
• 
  Multidisciplinary Care in ATTR-CM: Building the Right Team 20.08.2026 3min

  Guest: Sumeet Mitter MD, MSc, FACC Because transthyretin amyloid cardiomyopathy (ATTR-CM) is a systemic disease, effective ATTR-CM management requires expertise beyond cardiology. Dr. Sumeet Mitter joins us to discuss the roles of neurology, hematology-oncology, genetic counseling, and nephrology in caring for these patients. He's the Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia.
• 
  Building Clinical Expertise in ATTR-CM Management 20.08.2026 2min

  Guest: Sumeet Mitter MD, MSc, FACC As advances in RNA silencers, gene-editing technologies, and immunotherapy reshape the ATTR-CM landscape, it's important to stay informed and build confidence navigating this increasingly complex field. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, shares practical advice about navigating the nuances of this rare disease.
• 
  The Future of ATTR-CM Care: A Look at What's Next 20.08.2026 4min

  Guest: Sumeet Mitter MD, MSc, FACC The future of ATTR-CM care may extend beyond slowing disease progression to detecting it sooner—and potentially reversing its effects. Dr. Sumeet Mitter, Director of Inova Schar Heart and Vascular Research and the Infiltrative and Restrictive Cardiomyopathy Center at Inova Health in Virginia, explores emerging innovations that could open the door to earlier intervention, combination therapy, and even one-time treatment strategies.
• 
  Managing Acute PE: Updates from the 2026 AHA/ACC Guideline 20.08.2026 10min

  Host: Mary Leuchars, MD Guest: Mark Creager, MD The 2026 American College of Cardiology/American Heart Association Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults introduces a new clinical categorization framework to help evaluate risk and determine the appropriate care setting and treatment for patients with acute pulmonary embolism. Review key updates as Dr. Mary Leuchars sits down with Dr. Mark Creager, chair of the guideline writing committee. He's also a Professor of Medicine and Professor of Surgery at the Geisel School of Medicine at Dartmouth.
• 
  From Goals to Action: Multisociety Guidance on Lipid Management 19.08.2026 4min

  Guest: Ann Marie Navar, MD, PhD With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferences, and the treatment most likely to help patients achieve their LDL goals. Dr. Navar is an Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, and she served on the Guideline Writing Committee.
• 
  Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates 19.08.2026 4min

  Guest: Roger Blumenthal, MD What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  How PCSK9 Inhibition Lowers LDL Cholesterol 19.08.2026 2min

  Guest: Ann Marie Navar, MD, PhD How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.
• 
  Enlicitide for LDL-C Management: Insights from CORALreef Lipids 19.08.2026 4min

  Guest: Ann Marie Navar, MD, PhD The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for integrating this therapy into clinical practice.
• 
  Risk Prediction with the PREVENT-ASCVD Equations 19.08.2026 2min

  Guest: Roger Blumenthal, MD As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director of the Ciccarone Center for the Prevention of Cardiovascular Disease at Johns Hopkins Medicine.
• 
  The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice 14.08.2026 16min

  Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar.1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful evaluation for underlying causes and risk becomes important.4 That’s why Dr. Charles Turck sits down with Dr. Erin Michos to discuss what sHTG is, why it’s so important to identify, and how we can effectively manage this condition to improve patients’ overall health and reduce complication risk. Dr. Erin Michos is a Professor of Medicine, Director of Women’s Cardiovascular Health, and Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine. References: Saadatagah S, Larouche M, Naderian M, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978. doi:10.1016/j.ajpc.2025.100978 Sanchez RJ, Ge W, Wei W, Ponda MP, Rosenson RS. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 2021;20(1):72. doi:10.1186/s12944-021-01488-8 Sikora Kessler A, Baum SJ, Kutrieb E, et al. Rates …